Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies

被引：1

作者：

Kuboki, Yasutoshi ^{[1
]}

Furukawa, Masayuki ^{[2
]}

Takahashi, Yasuo ^{[3
]}

Mizuno, Nobumasa ^{[4
]}

Hara, Hiroki ^{[5
]}

Ueno, Makoto ^{[6
]}

Ioka, Tatsuya ^{[7
]}

Takahashi, Shunji ^{[8
]}

Shimizu, Toshio ^{[9
]}

Lihou, Christine F. ^{[10
]}

Tian, Chenwei ^{[10
]}

Ji, Tao ^{[10
]}

Fujiwara, Yutaka ^{[9
]}

机构：

[1] Natl Canc Cent Hosp East, Kashiwa, Chiba, Japan

[2] Kyushu Canc Ctr, Minami Ku, Fukuoka, Fukuoka, Japan

[3] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[5] Saitama Canc Ctr, Saitama, Japan

[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[7] Osaka Int Canc Inst, Osaka, Japan

[8] JFCR, Canc Inst Hosp, Koto Ku, Tokyo, Japan

[9] Natl Canc Ctr, Chuo Ku, Tokyo, Japan

[10] Incyte Corp, Wilmington, DE USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

10.1093/annonc/mdz343.034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1 - 156

引用

页数：1

共 50 条

[41] A Phase I study of indoximod in patients with advanced malignancies
Soliman, Hatem H.
Minton, Susan E.
Han, Hyo Sook
Ismail-Khan, Roohi
Neuger, Anthony
Khambati, Fatema
Noyes, David
Lush, Richard
Chiappori, Alberto A.
Roberts, John D.
Link, Charles
Vahanian, Nicholas N.
Mautino, Mario
Streicher, Howard
Sullivan, Daniel M.
Antonia, Scott J.
ONCOTARGET, 2016, 7 (16) : 22928 - 22938
[42] Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies
Ando, Yuichi
Doi, Toshihiko
Mitsuma, Ayako
Mizutani, Takefumi
Toyoda, Masanori
Imamura, Yoshinori
Kiyota, Naomi
Naito, Yoichi
Matsubara, Nobuaki
Ishihara, Kae
Tajima, Takeshi
Tokushige, Kota
Cameron, Scott
Minami, Hironobu
ANNALS OF ONCOLOGY, 2018, 29
[43] FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations
Feliz, Luis
Asatiani, Ekaterine
Lihou, Christine
Zhen, Huiling
Silverman, Ian
Ahnert, Jordi Rodon
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[44] Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies
Hatake, Kiyohiko
Chou, Takaaki
Doi, Toshihiko
Terui, Yasuhito
Kato, Harumi
Hirose, Takayuki
Seo, Sachiko
Pourdehnad, Michael
Ogaki, Yumi
Fujimoto, Hiroshi
Hagner, Patrick R.
Yamamoto, Kazuhito
CANCER SCIENCE, 2021, 112 (01) : 331 - 338
[45] Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Toshihiko Doi
Takayuki Yoshino
Nozomu Fuse
Narikazu Boku
Kentaro Yamazaki
Wasaburo Koizumi
Ken Shimada
Yasutaka Takinishi
Atsushi Ohtsu
Investigational New Drugs, 2015, 33 : 1068 - 1077
[46] Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Doi, Toshihiko
Yoshino, Takayuki
Fuse, Nozomu
Boku, Narikazu
Yamazaki, Kentaro
Koizumi, Wasaburo
Shimada, Ken
Takinishi, Yasutaka
Ohtsu, Atsushi
INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1068 - 1077
[47] Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors
Kuboki, Yasutoshi
Kondo, Shunsuke
Drew, Rasco
John, Powderly
Alexander, Spira
Jason, J. Luke
Daniel, Afar
Stefan, Englert
Hashiba, Hideyuki
Stacie, Lambert
Apurvasena, Parikh
Shimizu, Eisuke
Greg, Vosganian
Doi, Toshihiko
Yamamoto, Noboru
ANNALS OF ONCOLOGY, 2019, 30
[48] Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies
McGregor, Bradley Alexander
Campbell, Matthew T.
Xie, Wanling
Farah, Subrina
Bilen, Mehmet A.
Schmidt, Andrew L.
Sonpavde, Guru P.
Kilbridge, Kerry L.
Choudhury, Atish D.
Mortazavi, Amir
Shah, Amishi Y.
Venkatesan, Aradhana M.
Bubley, Glenn J.
Siefker-Radtke, Arlene O.
McKay, Rana R.
Choueiri, Toni K.
CANCER, 2021, 127 (06) : 840 - 849
[49] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
Naito, Yoichi
Kuboki, Yasutoshi
Ikeda, Masafumi
Harano, Kenichi
Matsubara, Nobuaki
Toyoizumi, Shigeyuki
Mori, Yuko
Hori, Natsuki
Nagasawa, Takashi
Kogawa, Takahiro
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
[50] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
Yoichi Naito
Yasutoshi Kuboki
Masafumi Ikeda
Kenichi Harano
Nobuaki Matsubara
Shigeyuki Toyoizumi
Yuko Mori
Natsuki Hori
Takashi Nagasawa
Takahiro Kogawa
Investigational New Drugs, 2021, 39 : 1568 - 1576

← 1 2 3 4 5 →